The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients

Overview

Journal Int J Prev Med

Date 2015 Nov 26

PMID 26605014

Citations 6

Authors

Mehri Rejali

Mehdi Tazhibi

Fariborz Mokarian

Nazjamal Gharanjik

Reyhane Mokarian

Affiliations

Soon will be listed here.

Abstract

Background: Prognostic tools are widely used in the practice of Oncology and have been developed to help stratify patients into specific risk-related grouping. We sought to apply of two such tools used for patients with early-stage breast cancer and to correlate them with actual outcomes.

Methods: A retrospective study was designed to include early-stage breast cancer cases seen from 1994 to 2014 at the Seyedoshohada Hospital in Isfahan, Iran. Information was derived from the patients' records, and indices were derived from prognostic tools. Information was analyzed using descriptive statistics and one sample t-test.

Results: In 233 patients, the difference between the predicted overall survival (OS) by the Adjuvant Online (AO) prognosis tools (69.28) and the observed OS (71.2) was not statistically significant (P = 0.52), and the AO prognosis tools had predicted the patients' OS correctly. In the Nottingham prognosis index (NPI), this difference in all groups except the very poor prognosis group was not statistically significant.

Conclusions: Adjuvant Online prognosis tools were capable of predicting the 10-year OS rate although not in all of the subgroups. The NPI was capable of distinguishing good, moderate, and poor survival rates, but this ability was not visible in more specific groups with moderate and poor prognosis.

Citing Articles

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.

Song R, Lee D, Lee E, Lee S, Kang H, Han J Cancers (Basel). 2023; 15(18).

PMID: 37760420 PMC: 10527468. DOI: 10.3390/cancers15184451.

Prognostic models for breast cancer: a systematic review.

Phung M, Tin Tin S, Elwood J BMC Cancer. 2019; 19(1):230.

PMID: 30871490 PMC: 6419427. DOI: 10.1186/s12885-019-5442-6.

Nottingham Prognostic Index is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer.

Al jarroudi O, Zaimi A, Brahmi S, Afqir S Asian Pac J Cancer Prev. 2019; 20(1):59-63.

PMID: 30678381 PMC: 6485561. DOI: 10.31557/APJCP.2019.20.1.59.

Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies.

Gray E, Donten A, Payne K, Hall P Syst Rev. 2018; 7(1):142.

PMID: 30219092 PMC: 6138917. DOI: 10.1186/s13643-018-0803-9.

Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer.

Zhen H, Yang L, Li L, Yu J, Zhao L, Li Y Oncotarget. 2017; 8(43):74096-74105.

PMID: 29088770 PMC: 5650325. DOI: 10.18632/oncotarget.18242.

References

Balslev I, Axelsson C, Zedeler K, Rasmussen B, Carstensen B, Mouridsen H . The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat. 1994; 32(3):281-90. DOI: 10.1007/BF00666005. View

Galea M, Blamey R, Elston C, Ellis I . The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22(3):207-19. DOI: 10.1007/BF01840834. View

Goldhirsch A, Ingle J, Gelber R, Coates A, Thurlimann B, Senn H . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8):1319-29. PMC: 2720818. DOI: 10.1093/annonc/mdp322. View

Campbell H, Taylor M, Harris A, Gray A . An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer. 2009; 101(7):1074-84. PMC: 2768087. DOI: 10.1038/sj.bjc.6605283. View

Brown J, Jones M, Benson E . Comment on the Nottingham Prognostic Index. Breast Cancer Res Treat. 1993; 25(3):283. DOI: 10.1007/BF00689843. View

Bhoo-Pathy N, Yip C, Hartman M, Saxena N, Taib N, Ho G . Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012; 48(7):982-9. DOI: 10.1016/j.ejca.2012.01.034. View

Clark G . Do we really need prognostic factors for breast cancer?. Breast Cancer Res Treat. 1994; 30(2):117-26. DOI: 10.1007/BF00666054. View

Blamey R, Davies C, Elston C, Johnson J, Haybittle J, Maynard P . Prognostic factors in breast cancer -- the formation of a prognostic index. Clin Oncol. 1979; 5(3):227-36. View

Carlson R, Brown E, Burstein H, Gradishar W, Hudis C, Loprinzi C . NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006; 4 Suppl 1:S1-26. View

10.

Haybittle J, Blamey R, Elston C, Johnson J, DOYLE P, Campbell F . A prognostic index in primary breast cancer. Br J Cancer. 1982; 45(3):361-6. PMC: 2010939. DOI: 10.1038/bjc.1982.62. View

11.

Mook S, Schmidt M, Rutgers E, van de Velde A, Visser O, Rutgers S . Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009; 10(11):1070-6. DOI: 10.1016/S1470-2045(09)70254-2. View

12.

Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A . Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3.... Ann Oncol. 2008; 20(2):258-64. DOI: 10.1093/annonc/mdn590. View

13.

Olivotto I, Bajdik C, Ravdin P, Speers C, Coldman A, Norris B . Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005; 23(12):2716-25. DOI: 10.1200/JCO.2005.06.178. View

14.

DEredita G, Giardina C, Martellotta M, Natale T, Ferrarese F . Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer. 2001; 37(5):591-6. DOI: 10.1016/s0959-8049(00)00435-4. View

15.

Ellis I, Bell J, Todd J, Williams M, Dowle C, Robins A . Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer. 1987; 56(3):295-9. PMC: 2002198. DOI: 10.1038/bjc.1987.192. View

16.

Jung M, Choi E, Nam C, Rha S, Jeung H, Lee S . Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. Ann Surg Oncol. 2013; 20(8):2615-24. DOI: 10.1245/s10434-013-2956-z. View

17.

Yao-Lung K, Dar-Ren C, Tsai-Wang C . Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis. BMC Med Inform Decis Mak. 2012; 12:108. PMC: 3502179. DOI: 10.1186/1472-6947-12-108. View

18.

Blamey R, Ellis I, Pinder S, Lee A, Macmillan R, Morgan D . Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer. 2007; 43(10):1548-55. DOI: 10.1016/j.ejca.2007.01.016. View

19.

Oakman C, Santarpia L, Di Leo A . Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 2010; 7(12):725-32. DOI: 10.1038/nrclinonc.2010.170. View

20.

Ravdin P, Siminoff L, Davis G, Mercer M, Hewlett J, Gerson N . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001; 19(4):980-91. DOI: 10.1200/JCO.2001.19.4.980. View